Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) was $19.64 for the day, down -9.89% from the previous closing price of $21.79. In other words, the price has decreased by -$9.89 from its previous closing price. On the day, 3.92 million shares were traded. CPRX stock price reached its highest trading level at $21.8 during the session, while it also had its lowest trading level at $19.15.
Ratios:
Our analysis of CPRX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.72. For the most recent quarter (mrq), Quick Ratio is recorded 6.55 and its Current Ratio is at 6.71. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on February 04, 2025, initiated with a Outperform rating and assigned the stock a target price of $28.
On November 18, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $35. On March 14, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $27.Citigroup initiated its Buy rating on March 14, 2024, with a $27 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 10 ’25 when Sundaram Preethi sold 2,324 shares for $26.41 per share. The transaction valued at 61,377 led to the insider holds 42,681 shares of the business.
Sundaram Preethi sold 1,600 shares of CPRX for $42,272 on Jun 11 ’25. The Chief Strategy Officer now owns 41,081 shares after completing the transaction at $26.42 per share. On Jun 11 ’25, another insider, Sundaram Preethi, who serves as the Officer of the company, bought 1,600 shares for $26.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 2394979072 and an Enterprise Value of 1752919424. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.91, and their Forward P/E ratio for the next fiscal year is 11.23. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.98. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.29 while its Price-to-Book (P/B) ratio in mrq is 2.81. Its current Enterprise Value per Revenue stands at 3.139 whereas that against EBITDA is 6.233.
Stock Price History:
The Beta on a monthly basis for CPRX is 0.85, which has changed by 0.062770605 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, CPRX has reached a high of $26.58, while it has fallen to a 52-week low of $16.06. The 50-Day Moving Average of the stock is -12.56%, while the 200-Day Moving Average is calculated to be -12.71%.
Shares Statistics:
CPRX traded an average of 1.29M shares per day over the past three months and 1505190 shares per day over the past ten days. A total of 122.39M shares are outstanding, with a floating share count of 111.17M. Insiders hold about 8.86% of the company’s shares, while institutions hold 79.47% stake in the company. Shares short for CPRX as of 1752537600 were 8915198 with a Short Ratio of 6.92, compared to 1749772800 on 7728086. Therefore, it implies a Short% of Shares Outstanding of 8915198 and a Short% of Float of 9.35.
Earnings Estimates
Catalyst Pharmaceuticals Inc (CPRX) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.43, with high estimates of $0.57 and low estimates of $0.27.
Analysts are recommending an EPS of between $2.39 and $2.08 for the fiscal current year, implying an average EPS of $2.26. EPS for the following year is $2.3, with 4.0 analysts recommending between $2.69 and $1.45.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $142.19M to a low estimate of $132M. As of the current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $128.69MFor the next quarter, 7 analysts are estimating revenue of $138.14M. There is a high estimate of $146M for the next quarter, whereas the lowest estimate is $133.11M.
A total of 7 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $566.4M, while the lowest revenue estimate was $551.76M, resulting in an average revenue estimate of $560.11M. In the same quarter a year ago, actual revenue was $491.73MBased on 7 analysts’ estimates, the company’s revenue will be $614.08M in the next fiscal year. The high estimate is $653.5M and the low estimate is $570.37M.
